Stay updated with breaking news from Astrazeneca Sponsored Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sanofi collaboration for Natural Killer cell engager therapeutics expanded to B7-H3 ANKETprogram and two additional targets, with €25 million payment Encouraging preliminary TELLOMAK Phase
Monalizumab and IPH5201 developed in collaboration with AstraZeneca advanced into Phase 3 and 2 clinical trials in lung cancer, triggering $55M in milestone payments Second preclinical asset
First patient dosed in monalizumab Phase 3 lung cancer trial, PACIFIC-9 sponsored by AstraZeneca, which triggered a $50 million milestone payment extending Company cash runway into 2024 Monalizumab
MARSEILLE, France--(BUSINESS WIRE)--May 10, 2022--